Ref | Study | Author & year | Country | Settinga | Study design | Prospect Retrosp | Date of data | MUAC stand | WHZ stand | Age range | Oed | Oed cases | “Both” in study | “Both” in survey | Time obs | Missing data | Default or lost | Original analysis |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# | # | year | mm | Z or % | month | % | % | % | d.m | % | % | |||||||
Studies giving numbers of children fulfilling both WHZ and MUAC criteria | ||||||||||||||||||
41 | 1 | Aguayo 2015 | India | IPF | Case notes | Retrosp | 2009–11 | < 115 | <− 3 WHO | 6–59 | excl | 63.9 | 21.3 | 14 d | ng | 22.9 | Log reg | |
42 | 2 | Grellety 2012 | Niger | Com | Com trial | Prospect | 2010 | < 115 | <−3 WHO | 6–23 | excl | 35.1 | 24.9 | 5 m | 5.3 | 0.0 | Cox PH reg | |
21 | 3 | Grellety 2015 | South Sudan | OTP | Case notes | Retrosp | 2008 | < 115 | <−3 WHO | 6–59 | excl | 31.7 | 20.3 | 51 d | 8.6 | 15.0 | Binom reg | |
43 | 4 | Isanaka 2015 | Niger | OTP | RCT | Prospect | 2012–3 | < 115 | <−3 WHO | 6–59 | excl | 39.2 | 24.9 | 29.5 d | 0.0 | 1.0 | Log-binom | |
44 | 5 | Lowlaavar 2016 | Uganda | IPF | Cohort | Prospect | 2012–3 | < 115 | <−3 WHO | 6–60 | excl | 22.5 | 11.6 | 3 d | ng | 9.7 | Log reg | |
45 | 6 | LaCourse 2014 | Malawi | IPF | Case notes | Prospect | 2011–2 | < 110 | < 70% NCHS | 6–60 | excl | 14.2 | 8.8 | ng | 0.5 | 0.0 | Chisq OR | |
35 | 7 | Olofin 2016 | DRC,Senegal,Nepal | Com | Com cohort | Prospect | 1983–92 | < 115 | <−3 WHO | 6–59 | excl | 21.9 | 20,12,7 | 2–6 m | ng | ng | Cox PH reg | |
Studies including oedema | ||||||||||||||||||
46 | 8 | Berkley 2005 | Kenya | IPF | Case notes | Prospect | 1999–02 | < 115 | <−3 NCHS | 12–59 | incl | 34.2 | 42.9 | 8.8b | ng | 3.6 | ng | ROC curve |
47 | 9 | Chiabi 2017 | Cameroun | IPF | Case notes | Retrosp | 2006–14 | < 115 | <− 3 WHO | 6–59 | incl | ng | 58.5 | 17.0 | ng | 30.7 | 10.1 | ROC curve |
48 | 10 | Sachdeva 2016 | India | IPF | Case notes | Prospect | 2012–3 | < 115 | <−3 WHO | 6–60 | incl | 3.8 | 32.2 | 21.3 | 3.7 d | ng | 15.0 | ROC curve |
Studies where children fulfilling both criteria are incorporated into both the WHZ and MUAC categories | ||||||||||||||||||
49 | 11 | Burza 2016 | India | Com | Follow up | Prospect | 2009–11 | < 115 | <−3 WHO | 6–59 | ng | ng | ng | 21.3 | 18 m | 26.7 | ng | Log reg |
50 | 12 | Mogeni 2011 | Kenya | IPF | Case notes | Prospect | 2007–9 | < 115 | <−3 WHO | 6–60 | incl | 19.2 | ng | 8.8b | ng | 5.4 | ng | Chisq |
51 | 13 | Sylla 2015 | Senegal | IPF | Case notes | Retrosp | 2012 | < 115 | <− 3 WHO | 0–60 | ng | ng | ng | 6.6 | ng | ng | ng | Log reg |
52 | 14 | Vella 1990 | Uganda | Com | Com cohort | Prospect | 1988 | < 115 | <−3 NCHS | 0–60 | incl | ng | ng | 11.6 | ng | 13.0 | 10.0 | Log reg |
53 | 15 | Dramaix 1993 | DRC | IPF | Case notes | Prospect | 1986–8 | < 115 | < 70% NCHS | 0–60 | incl | 28.9 | ng | 11.5 | 60 d | 15.4 | ng | Log reg |
54 | 16 | Girum 2017 | Ethiopia | IPF | Case notes | Retrosp | 2013–5 | < 115 | < 70% ng | ng | incl | 66.6 | ng | 15.5 | 13 d | ng | 11.6 | Cox PH reg |
55 | 17 | Savadogo 2007 | BFA | IPF | Case notes | Retrosp | 1999–03 | Tertile | <−3 NCHS | 0- < 36 | excl | ng | ng | 18.3 | 19 d | ng | 18.3 | Cox PH reg |
36 | 18 | Garenne1987 | Senegal | Com | Com cohort | Prospect | 1983–4 | < 115 | <−3 NCHS | 1–60 | incl | ng | ng | 6.6 | 3 m | ng | ng | Life table |
37 | 19 | Garenne 2009 | Senegal | Com | Com cohort | Prospect | 1983–4 | < 110 | CDC2000 | 1–60 | incl | ng | ng | 6.6 | 3 m | ng | ng | Life table |
37 | 20 | Garenne 2009 | DRC | Com | Com cohort | Prospect | 1989–92 | < 110 | CDC2000 | 1–60 | incl | ng | ng | 11.5 | 6 m | ng | ng | Life table |
38 | 21 | VD Broeck 1993 | DRC | Com | Com cohort | Prospect | 1989–92 | <−4 SD | <−3 NCHS | 0–60 | incl | ng | ng | 11.5 | 3 m | ng | ng | Life table |